Limelight Bio, Inc.

Limelight Bio, Inc. is a biotechnology company specializing in gene and cellular therapies, focusing on innovative solutions that enhance the development and manufacturing processes of these therapeutic applications. Founded in 2016 in Philadelphia, US, Limelight Bio focuses on providing solutions within the biotechnology sector. The company raised USD 25.

6 mn in Series A funding from Apple Tree Partners in October 2019, valuing the company at USD 32. 48 mn post-money. Limelight Bio specializes in providing innovative solutions within the biotechnology sector, focusing primarily on gene therapy and cellular therapies. Their core product offerings are designed to streamline the development and manufacturing processes of cell and gene therapies, ultimately enhancing the efficiency and effectiveness of therapeutic applications.

The company targets various end-use cases, including cancer treatment and rare genetic disorders, aiming to address significant unmet medical needs in these areas. Limelight Bio serves a diverse customer base that includes research institutions, pharmaceutical companies, and biotech firms located primarily in North America and Europe, enhancing their reach in these influential markets. Limelight Bio generates revenue through a structured model that focuses on partnerships with biotech and pharmaceutical firms, facilitating the development of cell and gene therapies. The company typically engages in B2B transactions, where clients may enter into agreements for services such as process development, clinical manufacturing, and regulatory support.

Pricing structures can vary based on the specific services rendered; however, offerings are tailored to meet the unique needs of each client, contributing to flexible engagement models. Flagship services include comprehensive support for therapy creation from conception through to regulatory approval, establishing Limelight Bio as a crucial partner within the biotechnology landscape. Limelight Bio plans to utilize the USD 25. 6 mn raised in Series A funding to enhance its product offerings and expand its market presence.

The company is currently designing new cell and gene therapies aimed at addressing additional rare genetic disorders, with anticipated launches in the coming years. Furthermore, Limelight Bio aims to expand its operations into Europe and Asia by 2025, targeting specific markets that have shown significant demand for innovative biotechnology solutions. This strategic expansion will help the company solidify its position in the biotechnology sector.